Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Somatic <i>ERCC2</i> Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

Eliezer M. Van Allen, Kent W. Mouw, Philip Kim et al. · Cancer Discovery · 2014 · 624 citations

Medicine, Molecular Biology, Oncology +17

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel et al. · European Journal of Cancer · 2005 · 545 citations

Medicine, Oncology, Urology +9

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Scott Saxman, Kathleen J. Propert, Lawrence H. Einhorn et al. · Journal of Clinical Oncology · 1997 · 496 citations

Medicine, Oncology, Pharmacology +8

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

Jane A. Plumb, Gordon Strathdee, Julieann Sludden et al. · PubMed · 2000 · 488 citations

Medicine, Cancer Biology, Oncology +16